Antiphospholipid Syndrome (APS) Market Size, Share, Trends, Growth, Key Companies, Emerging Drugs and Epidemiology Forecast

Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the immune system misguidedly creates antibodies that make one’s blood substantially more likely to clot. It is also known as Hughes syndrome or lupus anticoagulant syndrome. Those with APS make abnormal proteins known as antiphospholipid autoantibodies (aPL) in the blood. This causes blood to flow improperly and can prompt to dangerous clotting in arteries and veins, problems for a developing fetus, and pregnancy miscarriage.

Currently, there is no cure for APS, however, standard initial treatment involves a combination of blood-thinning medications. The most common are heparin and warfarin. Heparin is fast-acting and delivered via injections.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/antiphospholipid-syndrome-aps-market

DelveInsight’s “Antiphospholipid Syndrome (APS) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Antiphospholipid Syndrome (APS), historical and forecasted epidemiology as well as the Antiphospholipid Syndrome (APS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Antiphospholipid Syndrome (APS) market report also covers emerging drugs, current treatment practices, Antiphospholipid Syndrome (APS) market size and share of the individual therapies, current and forecasted Antiphospholipid Syndrome (APS) Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Antiphospholipid Syndrome (APS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Antiphospholipid Syndrome (APS) Market Key Facts

  • To estimate the annual incidence and prevalence of and frequency of mortality associated with APS, Duarte-García et al. (2019) conducted a population-based study. For that, an inception cohort of patients with incident APS in 2000–2015 from a geographically well-defined population was identified based on comprehensive individual medical records review. The investigators estimated the prevalence of 50 per 100,000 population for APS.
  • According to the American College of Rheumatology, Antiphospholipid antibodies are present in 15–20% of all cases of deep vein thrombosis (blood clots) and one-third of new strokes occurring in people under the age of 50.
  • According to American College of Rheumatology (2021) it was reported that antiphospholipid antibody syndrome affects women five times more commonly than men.
  • According to a study conducted by García et. al. (2019), the annual estimated prevalence of antiphospholipid antibody syndrome was 50 (95% CI 42–58) per 100,000 population.
  • According to a study by D’Cruz et. al. (2019), prevalence in the UK peaked at 50 (95% CI 49 – 55) in females in 2011 and 9.8 (95% CI 8.6 – 11.1) per 100,000 in males in 2012.
  • According to a study by Radin et. al. (2020), the prevalence cases of Antiphospholipid antibody syndrome in Italy are 40-50 cases per 100,000 persons and the diagnosis rate of Antiphospholipid antibody syndrome in Italy were 63% in aged of ≤50 years, 39% ≤40 years, and 18% ≤30 years.
  • According to an article by American College of Rheumatology (2021), it was reported that Antiphospholipid antibody syndrome affects women 5 times more commonly than men.

Key Benefits of Antiphospholipid Syndrome (APS) Market Report

  • Antiphospholipid Syndrome (APS) market report provides an in-depth analysis of Antiphospholipid Syndrome (APS) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
  • The Antiphospholipid Syndrome (APS) market report will help in developing business strategies by understanding the Antiphospholipid Syndrome (APS) Market trends & developments, key players, and future market competition that will shape and drive the Antiphospholipid Syndrome (APS) market in the upcoming years.
  • The Antiphospholipid Syndrome (APS) market report covers Antiphospholipid Syndrome (APS) market growth and current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
  • The report provides a detailed assessment of the Antiphospholipid Syndrome (APS) patient population, market drivers & barriers, Unmet Needs, market opportunities, comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Antiphospholipid Syndrome (APS) Market

The Antiphospholipid Syndrome (APS) market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Antiphospholipid Syndrome (APS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology. 

The report gives a thorough detail of Antiphospholipid Syndrome (APS) market trends and shares analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Antiphospholipid Syndrome (APS) Epidemiology

The Antiphospholipid Syndrome (APS) epidemiology section covers insights about historical and current Antiphospholipid Syndrome (APS) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted Antiphospholipid Syndrome (APS) epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Antiphospholipid Syndrome (APS) Drugs Uptake and Key Market Players

The Antiphospholipid Syndrome (APS) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Antiphospholipid Syndrome (APS) market or expected to get launched in the market during the study period. The analysis covers Antiphospholipid Syndrome (APS) market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Get FREE sample copy at:
https://www.delveinsight.com/sample-request/antiphospholipid-syndrome-aps-market

Table of Content

  1. Key Insights
  2. Executive Summary 
  3. Antiphospholipid Syndrome (APS) Competitive Intelligence Analysis
  4. Antiphospholipid Syndrome (APS) Market Overview at a Glance
  5. Antiphospholipid Syndrome (APS) Disease Background and Overview
  6. Antiphospholipid Syndrome (APS) Patient Journey
  7. Antiphospholipid Syndrome (APS) Epidemiology and Patient Population
  8. Antiphospholipid Syndrome (APS) Treatment Algorithm, Current Treatment, and Medical Practices
  9. Antiphospholipid Syndrome (APS) Unmet Needs
  10. Key Endpoints of Antiphospholipid Syndrome (APS) Treatment
  11. Antiphospholipid Syndrome (APS) Marketed Products
  12. Antiphospholipid Syndrome (APS) Emerging Therapies
  13. Antiphospholipid Syndrome (APS) Seven Major Market Analysis
  14. Attribute Analysis
  15. Antiphospholipid Syndrome (APS) Market Outlook (7 major markets)
  16. Antiphospholipid Syndrome (APS) Access and Reimbursement Overview
  17. KOL Views on the Antiphospholipid Syndrome (APS) Market.
  18. Antiphospholipid Syndrome (APS) Market Drivers
  19. Antiphospholipid Syndrome (APS) Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Related Reports
Antiphospholipid Syndrome (APS) Epidemiology Forecast
DelveInsight’s Antiphospholipid Syndrome (APS) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Antiphospholipid Syndrome (APS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Antiphospholipid Syndrome (APS) Pipeline Insights
Antiphospholipid Syndrome (APS) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Antiphospholipid Syndrome (APS) market.

Other Reports

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/
Connect With Us at:
LinkedIn | Facebook | Twitter

Get Free Sample Copy of Report at:
https://www.delveinsight.com/sample-request/antiphospholipid-syndrome-aps-market

Alopecia Areata Treatment Market Size, Epidemiology, Drugs Pipeline, Market Analysis and Companies by DelveInsight

Alopecia Areata (AA), an autoimmune skin disorder, in which the hair follicles get damaged by a faulty immune system. This faultiness causes the immune system to attack its own body, thus disrupting hair follicles and new hair formation. Biopsies performed have clearly shown the immune lymphocytes travelling in the hair bulbs of the hair follicle. The condition can lead to extreme hair loss in aggravated stages from the entire body, known as Alopecia universalis or it can lead to overall loss of hair from the scalp area, also called Alopecia Totalis.

DelveInsight’s “Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Alopecia Areata Symptoms

  • Patchy hair loss
  • Inflammation of the hair follicles
  • Cadaver hairs
  • White spots and lines appear
  • Pinpoint dents appear

Request for Free Sample Report: https://www.delveinsight.com/sample-request/alopecia-areata-market

Some facts of Alopecia Areata Market Report:

  • According to the Chantal Bolduc et al., 2018, the prevalence of alopecia areata (AA) in the general population is estimated to be 0.1–0.2%. The lifetime risk of developing alopecia areata is estimated to be 1.7%. All races are affected equally by alopecia areata and no increase in prevalence has been found in a particular ethnic group.
  • As per the study conducted by Alexandra C. Villasante Fricke et al. in 2015, the scalp is the most common site of involvement, with or without involvement of other body sites (such as the eyebrows, eyelashes, and beard). Specifically, the most common site was the occipital region, involved in 38.4% of males and 33.4% of females. Upon first presentation, 58% of adult patients had patchy hair loss with less than half the scalp involved. On the other hand, in children, 80–85% had mild-to-moderate hair loss involving less than half the scalp.
  • As per the National Organization of Rare Disease, alopecia areata is most common among the children and approximately 2.5 million people are suffering from alopecia areata in the United States.
  • As per Herbert Pratt et al. 2017, alopecia areata affects approximately two percent of the general population at some point during their lifetime
  • According to the National Alopecia Areata Foundation, approximately 6.8 million people in the United States and 147 million worldwide have or will develop alopecia areata at some point in their lives.
  • As per Alexandra C Villasante Fricke et al., 2015, patients with AA experience their first onset of AA by age 40 years in 82.6–88% of patients and by age 20 years in 40.2% of patients. The mean age of onset has been reported as between 25.2 and 36.3 years. In children, the mean age of onset has been reported as between ages 5 and 10 years.

Download Free Sample Report: https://www.delveinsight.com/sample-request/alopecia-areata-market

Alopecia Areata Treatment Market

The treatments commonly prescribed to AA patients include Injections, Oral, Topical Treatments and Light therapy.

Alopecia Areata Injections:

Steroid injections are commonly used in the treatment of AA, mainly for bald and patchy areas on the scalp. Steroidal injections are injected on the bare part of the affected area. Although it does not stop the hair fall, but effectively helps in regeneration of hair. The treatment is to be repeated in every one to two months.

Alopecia Areata Oral Treatments:

Cortisone tablets are majorly recommended for severe forms of AA. However, cortisone causes major side effects as well. Immunosuppressants such as methotrexate and cyclosporine are also recommended. They work by creating an obstruction for the immune system, but they cannot be ingested for prolonged periods due to serious side effects such as lymphoma, kidney and liver damages etc.

Alopecia Areata Topical Treatments:

Many types of topical treatments are rubbed on the scalp area and other regions of the body including eyebrows and beard. These involve Minoxidil (Rogaine), Anthralin (Dritho-Scalp), clobetasol (Impoyz), Diphencyprone etc.

Alopecia Areata Light Therapy:

This form of therapy uses a combination of psoralens and Ultra-violet light to treat AA.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/alopecia-areata-market

Some of Alopecia Areata Companies are:

  • Pfizer
  • Suzhou Zelgen Biopharmaceuticals
  • Eli Lilly and Company
  • Incyte Corporation
  • Aclaris Therapeutics
  • Legacy Healthcare
  • Concert Pharmaceuticals
  •  LEO Pharma
  • Bristol-Myers Squibb
  • And Many Others

Alopecia Areata Therapies are:

  • PF-06651600
  • Jaktinib
  • Baricitinib
  • ATI-502
  • Abatacept
  • LH-8
  • LEO 124249
  • CTP-543
  • And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/alopecia-areata-market

Table of Contents:

1. Key Insights

2. Executive Summary of Alopecia Areata

3. Competitive Intelligence Analysis for Alopecia Areata

4. Alopecia Areata: Market Overview at a Glance

4.1. Alopecia Areata Total Market Share (%) Distribution in 2018

4.2. Alopecia Areata Total Market Share (%) Distribution in 2030

5. Alopecia Areata: Disease Background and Overview

6. Patient Journey

7. Alopecia Areata Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Alopecia Areata Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Alopecia Areata: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Alopecia Areata

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Related Reports:

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Know More about our competitive intelligence services.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

 Company Name: DelveInsight Business Research LLP

 Contact Person: Ankit Nigam

 Email: info@delveinsight.com

 Phone: +19193216187

 City: Albany

 State: New York

 Country: United States

 Website: https://www.delveinsight.com/

Hearing Aid Devices Market Report 2026

The Global Hearing Aid Devices Market was valued at USD 6.69 billion in 2020, growing at a CAGR of 5.45% during the forecast period from 2021 to 2026, to reach USD 9.20 billion by 2026. The Hearing Aid Devices Market is slated towards a positive market growth owing to the factors such as growing burden of hearing loss along with the rising geriatric population. Moreover, long-term exposure to high decibel sounds leading to noise-induced hearing loss, technological advancement, and growing awareness regarding hearing loss and hearing aid devices, among others, will boost the market for hearing aid devices.

Some of the Global Hearing Aid Devices companies with their Hearing Aid products in various stages of development include Amplifon, Audina Hearing Instruments, Inc., Sonova, Demant A/S, audifon GmbH & Co. KG, GN Store Nord A/S, Arphi Electronics Private Limited, Foshan Vohom Technology Co., Ltd., RION Co., Ltd., Eargo Inc, Elkon Pvt Ltd., Starkey Laboratories, Inc., WS Audiology Denmark A/S, Horentek Hearing Diagnostics, Bernafon, Unitron,  MDHearingAid, Istok Audio Trading LLC, AlgorKorea Co., Ltd., Microson, and others. and others are currently dominating the Hearing Aid Devices Market.

DelveInsight’s “Hearing Aid Devices Market Insights and Forecast” report provides the current and forecasted Hearing Aid Devices Market trends for the next five years, upcoming innovation in the devices, individual Hearing Aid Devices market share, challenges, drivers and barriers, and key competitors in the domain.

View Report: https://www.delveinsight.com/report-store/hearing-aid-devices-market

Hearing Aid Devices Overview

Hearing aids are sound-amplifying devices designed to aid people who have a hearing impairment. Hearing aids differ by design and technology. The different styles of hearing aids are Behind-the-ear (BTE) aids, In-the-ear (ITE) aids, completely-in-the-canal (CIC) aids, among others.

 Are you interested to know how the Hearing Aid Devices Market will be growing by 2026? If yes, click to get a snapshot: https://www.delveinsight.com/sample-request/hearing-aid-devices-market

Recent Breakthroughs in Hearing Aid Devices Market

In recent years, the Hearing Aid Devices market observed expansions in terms of clinical, commercial, and clinical development.

  • In October 2021, Audibel, a brand of Starkey Hearing Technologies launched the “”Arc AI“” hearing aid line which uses artificial intelligence to adapt and adjust to the wearers’ environment.
  • In January 2021, Oticon launched the first-ever hearing aid built with an onboard deep neural network (DNN), Oticon More™.
  • In October 2020, Hansaton—a Sonova brand, launched two new hearing systems, the jazz XC Pro and the jam XC Pro, based on the EXCITE Pro platform. The two new product lineups aim to please both ITE wearers looking for advanced wireless features while maintaining discreet styling and BTE wearers looking for the familiarity of a replaceable battery system on hearing aids with the latest EXCITE Pro technology.

View Report: https://www.delveinsight.com/report-store/hearing-aid-devices-market

According to DelveInsight, the Hearing Aid Devices Clinical Development market would rise rapidly throughout the forecast period due to continuous commercial and clinical development.

Key Players Proactively working in the Hearing Aid Devices Market Insights

The global market for Hearing Aid Devices key players contribute significantly to their development and are also active in mergers and acquisitions to strengthen their market position. 

Some of the Hearing Aid Devices market companies operating actively in the Hearing Aid Devices included  Amplifon, Audina Hearing Instruments, Inc., Sonova, Demant A/S, audifon GmbH & Co. KG, GN Store Nord A/S, Arphi Electronics Private Limited, Foshan Vohom Technology Co., Ltd., RION Co., Ltd., Eargo Inc, Elkon Pvt Ltd., Starkey Laboratories, Inc., WS Audiology Denmark A/S, Horentek Hearing Diagnostics, Bernafon, Unitron,  MDHearingAid, Istok Audio Trading LLC, AlgorKorea Co., Ltd., Microson, and others.

Learn more about the Arthroscopy Surgery Device, get in-depth information @ https://www.delveinsight.com/sample-request/hearing-aid-devices-market

Scope of the Hearing Aid Devices Market Report

  • Geography Covered– Global
  • Study period- 2021-2026
  • Market Segmentation– By Product Type, By Application, By End User, By Geography
  • Porter’s Five Forces Analysis, Product Profiles, Cases Studies, KOL’s Views, and Analyst’s View

Table of Content

  1. Hearing Aid Devices Market Report Introduction
  2. Hearing Aid Devices  Executive Summary
  3. Hearing Aid Devices Regulatory and Patent Analysis
  4. Key Hearing Aid Devices Factors Analysis
  5. Porter’s Five Forces Analysis
  6. COVID-19 Impact Analysis
  7. Layout
  8. Global Hearing Aid Devices Company Share Analysis – Key 3-5 Companies
  9. Company and Product Profiles
  10. Project Approach
  11. KOL Views
  12. DelveInsight Capabilities
  13. Disclaimer
  14. About DelveInsight  

Key Takeaways from the Hearing Aid Devices Market Report Study

  • Market size analysis for current Hearing Aid Devices market size (2020), and market forecast for 5 years (2021-2026)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Hearing Aid Devices market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Various opportunities are available for the other competitor in the Hearing Aid Devices market space and dominating the global arthritis devices market companies
  • Which are the top-performing segments, regions, and countries in the current Hearing Aid Devices market scenario in 2020?
  • Which are the regions and countries where companies should have concentrated on opportunities for Hearing Aid Devices market growth in the coming future?

Are you interested to get information about the Hearing Aid Devices market? If yes, you are just one click away @ https://www.delveinsight.com/report-store/hearing-aid-devices-market

Other Reports:

Related Blogs:

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Size, Epidemiology, Therapies, Drugs and Key Companies by DelveInsight

DelveInsight’s “Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC), historical and forecasted epidemiology as well as the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market:

  • The highest number of NSCLC Cases were estimated in the United States.
  • According to DelveInsight’s assessment, in the United States, 7 out of 10 patients had metastatic NSCLC (Stage IIIb and IV).
  • The United States had 227,875 incident cases of Lung Cancer in 2020, of which ~85% were NSCLC cancer patient (GLOBOCAN, n.d..)
  • Among the European 5 countries, the Germany had highest cases of NSCLC. Furthermore, Japan accounts for about 117,752 cases in 2020.
  • DelveInsight’s analysts have estimated that in 2020, in the United States there were over 38,000 incident cases for EGFR mutation.

Request for Sample Report: https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market

View Report: https://www.delveinsight.com/report-store/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market

Scope of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market  Report

  • The report covers the descriptive overview of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market

NSCLC is the most common type of lung cancer and metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. Recent advances in understanding of cell signalling pathways that control cell survival have identified genetic and regulatory aberrations that suppress cell death, promote cell division, and induce tumorogenesis. One such discovery is that of epidermal growth factor receptor (EGFR). EGFR is a transmembrane receptor tyrosine kinase protein that is expressed in some normal epithelial, mesenchymal, and neurogenic tissue. Overexpression of EGFR has been reported and implicated in the pathogenesis of many human malignancies, including NSCLC. The EGFR gene may also undergo amplification, as detected by fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization (CISH).

Request for Sample Report: https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market

View Report: https://www.delveinsight.com/report-store/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market

Some of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Companies are:

  • Takeda
  • Yuhan Corporation
  • Janssen Research & Development
  • Novartis
  • Daiichi Sankyo
  • Astellas
  • Astrazeneca
  • And Many Others

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Therapies covered:

  • TAK-788 (mobocertinib)
  • Lazertinib (Leclaza)
  • Nazartinib (EGF816)
  • Patritumab deruxtecan (HER3-DXd)
  • And Many Others

Request for Sample Report: https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market

View Report: https://www.delveinsight.com/report-store/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market

Table of Contents:

1. Key Insights

2. Executive Summary of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)

3. Competitive Intelligence Analysis for Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)

4. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC): Market Overview at a Glance

5. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC): Disease Background and Overview

6. Patient Journey

7. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Unmet Needs

10. Key Endpoints of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Treatment

11. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Marketed Products

List to be continued in report

12. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Emerging Therapies

13. Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Other Reports:

Related Blogs:

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Hereditary Angioedema Market Research Report 2032

DelveInsight’s “Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx

HAE is a heterogeneous disease with complex pathophysiology that involves several pathways resulting in the increased production of bradykinin with mutations of multiple molecules in genetic etiology. These could include the Kallikrein gene mutations; Bradykinin gene or its receptor mutations; Kininase 1 gene mutations and loss of function and mutations in gene encoding aminopeptidase and ACE enzymes.

It is classified into three types based on genetic defects such as type I HAE with low levels of C1-INH in the body, type II with poorly functioning C1-INH, or the recently identified types of HAE with normal functioning C1-INH (formerly known as type III HAE). Identification of the novel polymorphisms in several genes leading to modification in the clinical phenotype of HAE is a relatively recent phenomenon. The clinical features of HAE are recurrent and unpredictable spontaneous edema attacks. Traumas, infections, stress, or medical procedures are potential triggers for HAE attacks, and occasionally, angioedema could be associated with prodromal signs, including erythema marginatum.

Get FREE sample copy at: 

https://www.delveinsight.com/sample-request/hereditary-angioedema-market

The Hereditary Angioedema market report also covers emerging drugs, current treatment practices, Hereditary Angioedema market share of the individual therapies, current and forecasted Hereditary Angioedema Market Size from 2019 to 2032 segmented by seven major markets. 

The report provides a detailed current Hereditary Angioedema treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 

Hereditary Angioedema Market Key Facts

  • Total diagnosed prevalent population of Hereditary Angioedema (HAE) in 7MM countries was estimated to be 14,435 cases in 2017.
  • Among the European countries, France had the highest prevalent population of 1,346 cases, followed by the UK which had prevalent population of 1,301 in 2017.
  • HAE in the US has been observed with the maximum number of diagnosed cases in the age-group 17 to below 65 years, followed by those who belong to the age-group 12 to less than 17 years.
  • Among the European 5 countries, Spain had the lowest prevalent population with 537 cases in 2017.

Key Benefits of Hereditary Angioedema Market Report

  • Hereditary Angioedema market report provides an in-depth analysis of Hereditary Angioedema Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
  • The Hereditary Angioedema market report will help in developing business strategies by understanding the Hereditary Angioedema Market trends & developments, key players and future market competition that will shape and drive the Hereditary Angioedema market in the upcoming years.
  • The Hereditary Angioedema market report covers Hereditary Angioedema current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
  • The report provides a detailed assessment of the Hereditary Angioedema market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Hereditary Angioedema Market

The landscape of therapeutic options for patients with HAE has changed dramatically in the last two decades. Ongoing research promises even greater change in the foreseeable future. Given the economic and psychosocial burdens for patients living with angioedema, effective therapies with novel mechanisms will offer more choices for patients and physicians, as well as provide greater flexibility in routes of administration. Owing to the launch of upcoming therapies, market size shall increase during forecast period (2017-2030).

The Hereditary Angioedema market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hereditary Angioedema market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Hereditary Angioedema market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Hereditary Angioedema Epidemiology

The Hereditary Angioedema epidemiology section covers insights about historical and current Hereditary Angioedema patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Hereditary Angioedema Drugs Uptake and Key Market Players

The Hereditary Angioedema Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to get launched in the market during the study period. The analysis covers Hereditary Angioedema market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Companies are focusing on executing a successful launch that meets the urgent demand for a once-daily oral therapy that will allow HAE patients to live a more normal life. An orally delivered, small molecule offers the opportunity to improve treatment for the disease by making it more convenient for patients to take therapies

Some of the key players in the Hereditary Angioedema Market includes:

  • BioCryst Pharmaceuticals
  • Ionis Pharmaceuticals
  • KalVista Pharmaceuticals
  • CSL Behring
  • Takeda
  • Shire
  • Pharming Group
  • And many others.

Hereditary Angioedema Drugs Covered

  • BCX7353
  • IONIS-PKK-LRx
  • KVD900
  • CSL312
  • And many others.

Table of Content

1. Key Insights

2. Executive Summary 

3. Hereditary Angioedema Competitive Intelligence Analysis

4. Hereditary Angioedema Market Overview at a Glance

5. Hereditary Angioedema Disease Background and Overview

6. Hereditary Angioedema Patient Journey

7. Hereditary Angioedema Epidemiology and Patient Population

8. Hereditary Angioedema Treatment Algorithm, Current Treatment, and Medical Practices

9. Hereditary Angioedema Unmet Needs

10. Key Endpoints of Hereditary Angioedema Treatment

11. Hereditary Angioedema Marketed Products

12. Hereditary Angioedema Emerging Therapies

13. Hereditary Angioedema Seven Major Market Analysis

14. Attribute Analysis

15. Hereditary Angioedema Market Outlook (7 major markets)

16. Hereditary Angioedema Access and Reimbursement Overview

17. KOL Views on the Hereditary Angioedema Market.

18. Hereditary Angioedema Market Drivers

19. Hereditary Angioedema Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Other Reports:

Related Blogs:

Arthroscopy Device Market Report 2026

The Global Arthroscopy Devices Market was valued at USD 1.57 billion in 2020, growing at a CAGR of 6.34% during the forecast period from 2021 to 2026 to reach USD 2.26 billion by 2026. The arthroscopy devices market is slated towards a positive market growth owing to the factors such as the increasing geriatric population, rising prevalence of degenerative bone disorders, growing number of trauma cases and sports-related injuries, increasing popularity of minimally invasive procedures, and increasing product development activities among other factors.

Some of the Global Arthroscopy Device companies with their Arthroscopy surgery products in various stages of development include Stryker, Zimmer Biomet, DePuy Synthes (Medical Devices Business Services, Inc.), Medtronic, Globus Medical, Olympus, DJO LLC, Richard Wolf GmbH, Active Implants, CONMED Corporation, EndoMed Systems, RUDOLF Medical GmbH + Co. KG, COMEG Medical Technologies, Gimmi® GmbH, Vimax Sp. z o.o., Smith and Nephew, KARL STORZ SE & Co. KG, SCHÖLLY FIBEROPTIC GMBH, Medacta International, and others are currently dominating the Arthroscopy Device Market.

DelveInsight’s “Arthroscopy Device Market Insights and Forecast” report provides the current and forecasted Arthroscopy Device Market trends for the next five years, upcoming innovation in the devices, individual Arthroscopy Devices market share, challenges, drivers and barriers, and key competitors in the domain.

Arthroscopy Device Overview

Arthroscopy devices are used in the examination of bone joints for specific conditions, such as rheumatoid arthritis, osteoarthritis, tendinitis, and bone tumor among others.  Orthopedic Devices are medical devices used as an implant manufactured for the replacement of a missing joint or bone or to support a damaged bone. 

The Arthroscopy devices are designed to prevent or manage musculoskeletal problems. Arthroscopy is a diagnostic and treatment procedure for joint issues. A surgeon makes a small incision about the size of a buttonhole and inserts a slender tube coupled to a fiber-optic video camera. A high-definition video monitor displays the view inside your joint.

Are you interested to know how the Arthroscopy Device Market will be growing by 2026? If yes, click to get a snapshot: https://www.delveinsight.com/report-store/arthroscopy-devices-market

Recent Breakthroughs in Arthroscopy Device Market

In recent years, the Arthroscopy Device market observed expansions in terms of clinical, commercial, and clinical development.

  • In July 2021, Stryker received clearance from the US FDA for the first balloon implant for arthroscopic treatment of massive irreparable rotator cuff tears (MIRCTs).
  • In June 2021, Arthrocare Corporation (acquired by Smith and Nephew) received the 510k approval from the US FDA for their product- Werewolf+ Coblation System, Werewolf+ Controller, Werewolf Fastseal 6.0 Hemostasis Wand.
  • In June 2020, Medacta International received the CE mark approval for their Long Humeral Diaphysis and Stemless Humeral Metaphysis implants used in the shoulder joint replacement.

According to DelveInsight, the Arthroscopy Device Clinical Development market would rise rapidly throughout the forecast period due to continuous commercial and clinical development.

Key Players Proactively working in the Arthroscopy Device Market Insights

The global market for Arthroscopy Device key players contribute significantly to their development and are also active in mergers and acquisitions to strengthen their market position. 

Some of the Arthroscopy Device market companies operating actively in the Arthroscopy Device included  Stryker, Zimmer Biomet, DePuy Synthes (Medical Devices Business Services, Inc.), Medtronic, Globus Medical, Olympus, DJO LLC, Richard Wolf GmbH, Active Implants, CONMED Corporation, EndoMed Systems, RUDOLF Medical GmbH + Co. KG, COMEG Medical Technologies, Gimmi® GmbH, Vimax Sp. z o.o., Smith and Nephew, KARL STORZ SE & Co. KG, SCHÖLLY FIBEROPTIC GMBH, Medacta International, and others.

Learn more about the Arthroscopy Surgery Device, get in-depth information @ https://www.delveinsight.com/report-store/arthroscopy-devices-market

COVID-19 Impact Analysis on Arthroscopy Device Market

The growing popularity of minimally invasive procedures has also been instrumental in driving the demand for arthroscopy procedures and eventually boosting the growth of the arthroscopy devices market. Compared to ‘open’ surgery, arthroscopy surgeries offer faster healing time, less pain after the operation, and the ability to resume daily activities faster. 

This is one of the key factors resulting in the commendable growth of the arthroscopy devices market. However, complications associated with the arthroscopy procedures as well as a temporary setback in the product demand due to the COVID-19 pandemic are some impeding factors to the arthroscopy devices market growth.

As per the article “The Injury Rate in National Football League Players Increased Following Cancellation of Preseason Games Because of COVID-19” published in 2021 by Baker et al., 3,025 injuries were reported over the course of 4 NFL study seasons (2016-2020). Of the 3,025 reported injuries, 582 (19%) occurred in week 14 of the 2020-2021 regular season, while 1,292 (53%) occurred in week 14 of preseason and 1,151 (38%) in regular-season 14 of the 2016-2017 season. 

Request a snapshot of the report, just a click here to know @ https://www.delveinsight.com/report-store/arthroscopy-devices-market

Scope of the Arthroscopy Device Market Report

  • Geography Covered– Global
  • Study period- 2021-2026
  • Market Segmentation– By Product Type, By Application, By End User, By Geography
  • Key Global Arthroscopy Device Companies in the Market:  Stryker (NYSE: SYK), Zimmer Biomet (NYSE: ZBH), DePuy Synthes (Medical Devices Business Services, Inc.), Medtronic (NYSE: MDT), Globus Medical (NYSE: GMED), Olympus (NYSE: OCPNY), DJO LLC, Richard Wolf GmbH, Active Implants, CONMED Corporation (NYSE: CNMD), EndoMed Systems, RUDOLF Medical GmbH + Co. KG, COMEG Medical Technologies, Gimmi® GmbH, Vanguard Mid-Cap Index Fund Admiral Shares (NYSE: VIMAX), Smith and Nephew (NYSE: SNN), KARL STORZ SE & Co. KG, SCHÖLLY FIBEROPTIC GMBH, Medacta International, and others.
  • Porter’s Five Forces Analysis, Product Profiles, Cases Studies, KOL’s Views, a0nd Analyst’s View

Table of Content

  1. Report Introduction
  2. Executive Summary
  3. Regulatory and Patent Analysis
  4. Key Factors Analysis
  5. Porter’s Five Forces Analysis
  6. COVID-19 Impact Analysis
  7. Layout
  8. Global Company Share Analysis – Key 3-5 Companies
  9. Company and Product Profiles
  10. Project Approach
  11. KOL Views
  12. DelveInsight Capabilities
  13. Disclaimer
  14. About DelveInsight  

Key Takeaways from the Arthroscopy Devices Market Report Study

  • Market size analysis for current arthroscopy devices market size (2020), and market forecast for 5 years (2021-2026)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the arthroscopy devices market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Various opportunities are available for the other competitor in the arthroscopy devices market space and dominating the global arthritis devices market companies
  • Which are the top-performing segments, regions, and countries in the current arthroscopy devices market scenario in 2020?
  • Which are the regions and countries where companies should have concentrated on opportunities for arthroscopy devices market growth in the coming future?

Are you interested to get information about the Arthroscopy Device market? If yes, you are just one click away @ https://www.delveinsight.com/report-store/arthroscopy-devices-market

Other Reports:

Related Blogs:

Pre-filled Syringes Market Size, Epidemiology, Devices, Market Segmentation and Companies by DelveInsight

DelveInsight’s “Pre filled Syringes Market Insights, Competitive Landscape and Market Forecast-2026” report delivers an in-depth understanding of the Pre filled Syringes, historical and forecasted epidemiology as well as the Pre filled Syringes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent developmental activities in Pre filled Syringes market

  • According to DelveInsight, the pre-filled syringe market will increase at a CAGR of 10.40 percent during the forecasted period from 2021 to 2026, to reach USD 18.76 billion by 2026.  
  • In July 2021, Fresenius Kabi launched ready-to-administer prefilled fentanyl syringe in the 1 ml volume format which is designed to cut waste and diversion by eliminating the possibilities of potential errors.
  • In May 2021, Glenmark Pharmaceuticals Limited received the US Food and Drug Administration approval for the  Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe.
  • In April 2021, Roche received the approval from the US FDA for the supplemental Biologics License Application of the company for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.
  • In March 2021, Zealand Pharma announced the US FDA approval for the Zegalogue® (dasiglucagon) injection which is available in the prefilled syringe form, for the treatment of diabetes.

For more insights into Pre filled Syringes Market, get the snapshot of the key highlights @ https://www.delveinsight.com/report-store/prefilled-syringes-market

Pre filled Syringes Overview

A prefilled syringe is a single-dose packet of vaccine to which a needle has been fixed by the manufacturer. In the past metal or glass syringes were popular, but increasingly there has been a movement towards plastic and disposable syringes so the needle is protected and cannot be reused (prefilled disposable systems). This has stimulated the demand for convenient and safe prefilled syringes. 

Prefilled syringes have been around for more than two decades. Prefilled syringe manufacturers have had to therefore respond to increasing demand, new requirements and more sophisticated forms of drug delivery. There has been great development in syringes. New products are being put in syringes now. Prefilled syringes are used to package injectable drugs and diluents. Some of the categories of drugs packaged in prefilled syringes are vaccines, blood stimulants, therapeutic proteins, erythro proteins, interferons, and rheumatoid arthritis.

Interested in knowing how the Pre filled Syringes Market will be growing by 2026? Click to get a snapshot of Pre filled Syringes Analysis : https://www.delveinsight.com/report-store/prefilled-syringes-market

Geography Wise- Pre filled Syringes Market Analysis

The Blood Glucose Monitoring System market is analyzed geographically for North America, Europe, Asia-Pacific, and the Rest of the World.Among all the regions, North America is expected to account for the significant market share in the prefilled syringes market because of the high prevalence of autoimmune disorders, chronic diseases, rising population of the elderly as well as high awareness among people regarding disease management and the new product launches in the region.

 The North American prefilled syringes market is witnessing an upward trend due to the rising prevalence of autoimmune diseases among other factors. In a study published in the journal Arthritis and Rheumatology by Dinse et al. in 2020, the researchers found that the prevalence of antinuclear antibodies (ANA), the most common biomarkers of autoimmunity, is increasing significantly in the United States in general, and more specifically in certain groups. Therefore, in order to cater to the medical needs of the large population suffering from autoimmune diseases such as RA, a number of medications are available in the prefilled syringes form. The well-established patient care system along with awareness among patients and caregivers regarding different types of prefilled syringes is further expected to propel the North American prefilled syringes market growth.

Segmentation

By Product Design 

  • Staked Needle System
  • Luer Cone System,
  • Luer Lock System

By Material 

  • Glass
  • Polymer

By Usability 

  • Reusable 
  • Disposable

By End User 

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  •  Homecare Settings
  • and Others

By Geography 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Get a sneak peek at the Pre filled Syringes Market market dynamics @ https://www.delveinsight.com/report-store/prefilled-syringes-market

Pre filled Syringes Market Segment Analysis

In the material segment of the prefilled syringes market, there is expected to be a shift from glass to polymer (plastic) syringes in the forecast period in order to overcome the shortcomings of the prefilled syringes made of glass. For instance, silicone oil (used to lubricate the inner surface of glass pre-filled syringe) is seen as a key factor which cannot be avoided in the manufacture of glass prefilled syringes yet is known to interfere with the properties of the biologics. Silicone is needed to ensure functionality, for components for prefilled syringes such as the plunger but silicone can alter sensitive proteins under certain conditions—causing them to aggregate or change their form. Therefore, polymer prefilled syringes are now being preferred over the glass prefilled syringes. The polymer prefilled syringes have high barrier properties against water vapor and oxygen, thereby effectively protecting the contents of the syringe. These syringes are also transparent, and are remarkably similar in appearance to glass syringes. This transparency also makes it easy to visually check content for haze, particles, and other imperfections. The Cyclo-Olefin-Polymer (COP) syringes are also much more resistant to breakage than their glass counterparts. Thus, the factors mentioned above are going to be instrumental in the increasing demand for plastic prefilled syringes in the forecast period.

Pre filled Syringes Market Scope

Study Period: 2018-2026

Key Companies: BD, NIPRO Pharma, Taisei Kako Co.,Ltd, TERUMO PHARMACEUTICAL SOLUTIONS., SCHOTT AG, Gerresheimer AG, West Pharmaceutical Services, Inc., Dali Medical Devices, Stevanato Group, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL Inc, IRISYS, LLC, Sandoz International GmbH, Pfizer Inc., Vetter, Weigao Group, Fresenius Kabi, Catalent Inc and others.

Segmentation: By Product Design, By Material, By Usability, By End User, By Geography

Geography Covered: North America, Europe, Asia- Pacific, Rest of the World (Middle East, Africa, and South America)

Know more about which MedTech player is set to emerge as the trendsetter @ https://www.delveinsight.com/report-store/prefilled-syringes-market

Table of Contents

  1. Prefilled Syringes Market Report Introduction
  2. Prefilled Syringes Market Executive Summary
  3. Regulatory and Patent Analysis
  4. Prefilled Syringes Market Key Factors Analysis
  5. Prefilled Syringes  Market Porter’s Five Forces Analysis
  6. COVID-19 Impact Analysis on Prefilled Syringes Market
  7. Prefilled Syringes Market Layout
  8. Prefilled Syringes Market Global Company Share Analysis – Key 3-5 Companies
  9. Prefilled Syringes Market Company and Product Profiles
  10. Project Approach
  11. KOL Views
  12. DelveInsight Capabilities
  13. Disclaimer
  14. About DelveInsight

Learn more about the Pre filled Syringes @ Prefilled Syringes Regulatory And Patent Analysis

Other Reports:

Related Blogs:

The Brain/Cranial Implants market size is expected to rise at a significant CAGR during 2018-2026, assess DelveInsight

DelveInsight’s “Brain/Cranial Implants Market Insights, Competitive Landscape and Market Forecast-2026” report delivers an in-depth understanding of the Brain/Cranial Implants, historical and forecasted epidemiology as well as the Brain/Cranial Implants market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent developmental activities in Brain/Cranial Implants market

  • In January 2021, Longeviti Neuro Solutions received the 510 k clearance from the US Food and Drug Administration for their ClearFit Cranial Implant for postoperative ultrasound imaging.
  • In September 2020, OssDsign AB received patent coverage from the United States Patent and Trademarks Office (USPTO) for the implant design for OssDsign Cranial PSI. The company had previously received the patent in Europe, Japan, and Australia.
  • As per an estimate by DelveInsight, Global Brain/Cranial Implants Market is anticipated to grow at a tremendous CAGR of 6.10% during the forecast period from 2021 to 2026, and is also expected to reach USD 1.47 billion by 2026.

For more insights into Brain/Cranial Implants, get the snapshot of the key highlights @ https://www.delveinsight.com/report-store/brain-cranial-implants-market

Brain/Cranial Implants Overview

Cranial bone defects can affect a patient’s life quality. Such defects can originate from infections of the calvaria, from heavy craniofacial traumas such as traffic and sports accidents and other physical assaults that occur due to congenital craniofacial deformities or as side effects after neurosurgical or maxillofacial procedures. Brain/Cranial Implants or reconstruction is required for restoring the skull contour, protecting intracranial structures, and normalizing cerebral hemodynamics. Traditional methods of cranial reconstruction majorly focus on bone reconstruction and do not account for the soft tissues. If soft tissues are not addressed, they may lead to deformity after surgeries. The development of technologically advanced products such as customized cranial implants and 3D printing help overcome the issues associated with traditional methods.

​Get a sneak peek at the Brain/Cranial Implants Market dynamics @ https://www.delveinsight.com/report-store/brain-cranial-implants-market

Some of key Brain/Cranial Implants companies in the market are: Stryker, Zimmer Biomet, DePuy Synthes (Medical Devices Business Services, Inc.), Medtronic, KELYNIAM GLOBAL INC, B. Braun Melsungen AG, Jeil Medical Corporation, Longeviti Neuro Solutions LLC, MedCAD, and others.

Geography Wise- Brain/Cranial Implants Market Analysis

Geographically, the global bradycardia market can be segmented into North America, Europe, Asia- Pacific, Rest of the World (Middle East, Africa, and South America). In terms of revenue share North America currently leads the global market and is expected to remain constant during the forecast period. This domination is observed majorly owing to the growing number of traumatic brain injuries, access to better healthcare infrastructure along with the presence of major market players in the region.

According to the estimates by DelveInsight, in the product segment of the brain/cranial implants market, the customized Brain/Cranial Implants are expected to account for the larger market share. Customized Brain/Cranial implants, also known as patient-specific implants, are plate-type medical devices that differ by their size and configurations (depending on the size and location of the cranial defect) and that are used in cranioplasty to correct cranial defects.

Brain/Cranial Implants Market Scope

  • Study Period: 2018-2026
  • Key Brain/Cranial Implants Companies: Stryker, Zimmer Biomet, DePuy Synthes (Medical Devices Business Services, Inc.), Medtronic, KELYNIAM GLOBAL INC, B. Braun Melsungen AG, Jeil Medical Corporation, Longeviti Neuro Solutions LLC, MedCAD, and others.
  • Geography Covered: North America, Europe, Asia- Pacific, Rest of the World (Middle East, Africa, and South America)
  • Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s View, Analyst’s View

Table of Contents

  1. Brain/Cranial Implants Market Report Introduction
  2. Brain/Cranial Implants Market Executive summary
  3. Regulatory and Patent Analysis
  4. Brain/Cranial Implants Market Key factors analysis
  5. Brain/Cranial Implants Porter’s Five Forces Analysis
  6. COVID-19 Impact Analysis on Brain/Cranial Implants Market
  7. Brain/Cranial Implants Market layout
  8. Brain/Cranial Implants Global Company Share Analysis – Key 3-5 Companies
  9. Brain/Cranial Implants Company and Product Profiles
  10. Project Approach
  11. KOL Views
  12. DelveInsight Capabilities
  13. Disclaimer
  14. About DelveInsight

Other Reports:

Related Blogs:

Hearing Implants Market

DelveInsight’s “Hearing Implants Market Insights, Competitive Landscape and Market Forecast-2026” report delivers an in-depth understanding of the Hearing Implants, historical and forecasted epidemiology as well as the Hearing Implants market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent developmental activities in Hearing Implants market

  • According to DelveInsight, the global Hearing Implants market will increase at a CAGR of 7.38 percent during the forecasted period from 2021 to 2026.
  • In June 2021, Oticon received FDA pre-market approval (PMA) for its Neuro Cochlear implant system indicated to treat severe to profound sensorineural hearing loss.
  • In March 2021, Cochlear received FDA clearance for Baha 6 Max, the industry’s smallest 55 dB sound processor with direct android streaming.
  • In July 2020, Cochlear received FDA approval for three new products in its arena of hearing technology solutions. The approved products are Kanso® 2 Sound Processor, Nucleus® 7 Sound Processor for Nucleus 22 Implant recipients, and Custom Sound® Pro fitting software.
  • In December 2020, Sonova Holding AG acquired a 3.7% ownership stake in Sensorion, a clinical-stage biotechnology company that specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders.

View Report: https://www.delveinsight.com/report-store/hearing-implants-market

Hearing Implants Overview

A hearing implant is a small, complex electronic device that can help to provide a sense of sound to a person who’s behind the ear and a second portion that is surgically placed under the skin (see figure). 

An implant has the following parts:

  • A microphone, which picks up sound from the environment.
  • A speech processor, which selects and arranges sounds picked up by the microphone.
  • A transmitter and receiver/stimulator, which receive signals from the speech processor and convert them into electric impulses.
  • An electrode array, which is a group of electrodes that collects the impulses from the stimulator and sends them to different regions of the auditory nerve.

An implant does not restore normal hearing. Instead, it can give a deaf person a useful representation of sounds in the environment and help him or her to understand speech.

View Report: https://www.delveinsight.com/report-store/hearing-implants-market

Geography Wise- Hearing Implants Market Analysis

The Hearing Implants market is analyzed geographically for North America, Europe, Asia-Pacific, and the Rest of the World. Among all the regions, Europe is expected to occupy a major share in the overall hearing implants market during the forecasted period. This domination is due to the growing cases of hearing loss in the region. According to the numbers released by the European Federation of Hard of Hearing People in the year 2021, an estimated 52 million Europeans suffer from hearing disabilities ranging from mild hearing loss to profoundly deafness. Thus, the escalating population suffering from mild to severe hearing disability in the region could be a potential factor for raising the hearing implant market in the region. Moreover, the presence of leading manufacturers such as MED-EL Medical Electronics, Sonova, and Demant A/S, among others in the region holding the major share of the market is also expected to bolster the market for hearing implants.

Segmentation

By Product Type 

  • Cochlear Implants
  • Middle Ear Implants
  • Bone Conduction Implants
  • Auditory Brainstem Implants

By Processor Type 

  • Behind The Ear Processor 
  • Body-Worn Processor

By Application 

  • Conductive Hearing Loss
  • Mixed Hearing Loss
  • Sensorineural Hearing Loss

By End-User 

  • Hospitals
  • Ent Clinics
  • And Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

View Report: https://www.delveinsight.com/report-store/hearing-implants-market

Hearing Implants Segment Analysis

In the hearing implants product segment, the cochlear implants segment is projected to hold the largest market share during the forthcoming years. The rise in the adoption of cochlear implants by the population across the globe is one of the key factors contributing to the segment growth. According to the National Institute on Deafness and Other Communication Disorders 2021 data, approximately 736,900 cochlear implants were implanted worldwide by the end of the year 2019. Cochlear implants are widely preferred by the target population as they are cost-effective and are available in both unilateral and bilateral fitting types. Additionally, an increase in approval of a variety of cochlear implants is also anticipated to augment the cochlear implant market growth. For instance, in March 2020, Cochlear Ltd. received FDA approval for its Nucleus 24 Cochlear Implant System intended to provide hearing to patients 9 months of age and older.

Impact of Covid-19 on Hearing Implants Market

The unprecedented outbreak of the COVID-19 pandemic has slowed down the market growth for hearing implants. This is because, with the rise of COVID-19 cases, the government across the globe implemented various safety measures such as lockdown and stringent guidelines which disrupted the supply chain of hearing implants internationally. Hearing implants are surgically placed inside the ear. Therefore, the cancellation of elective surgeries in the hospital during the pandemic situation to prevent the transmission of the disease among the patients as most of the population receiving hearing implants belong to the old age group also impacted the hearing implants market. However, due to the launch of vaccines, the post-pandemic situation of the market is expected to gain normalcy as manufacturers have increased their manufacturing capabilities along with hospitals resuming elective surgical procedures.

Hearing Implants Market Scope

Study Period: 2018-2026

Key Companies: MED-EL Medical Electronics., Sonova, Demant A/S, Medtronic, Cochlear Limited, Envoy Medical., Ototronix, TODOC Co., Ltd., and others.

Segmentation: By Product Type, By Processor Type, By Application, By End-User, By geography

Geography Covered: North America, Europe, Asia- Pacific, Rest of the World (Middle East, Africa, and South America)

Table of Contents

  1. Hearing implants Market Report Introduction
  2. Hearing implants Market Executive summary
  3. Regulatory and Patent Analysis
  4. Hearing implants Market Key factors analysis
  5. Hearing implants Porter’s Five Forces Analysis
  6. COVID-19 Impact Analysis on Hearing implants Market
  7. Hearing implants Market layout
  8. Hearing implants Global Company Share Analysis – Key 2-3 Companies
  9. Hearing implants Company and Product Profiles
  10. Project Approach
  11. KOL Views
  12. DelveInsight Capabilities
  13. Disclaimer
  14. About DelveInsight

Other Reports:

Related Blogs:

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/

Connect With Us at:

LinkedIn | Facebook | Twitter

Hemodynamic Monitoring Systems Market

DelveInsight’s “Hemodynamic Monitoring Systems Market Insights, Competitive Landscape and Market Forecast-2026” report delivers an in-depth understanding of the Hemodynamic Monitoring Systems, historical and forecasted epidemiology as well as the Hemodynamic Monitoring Systems market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent developmental activities in Hemodynamic Monitoring Systems market

  • According to DelveInsight, the Hemodynamic Monitoring Systems market will increase at a CAGR of 6.29 percent during the forecasted period from 2021 to 2026, to reach USD 924 million by 2026.  
  • In October 2020, Getinge launched NICCI – the latest innovation in Advanced Hemodynamic Monitoring. NICCI was Getinge’s latest innovation in Advanced Hemodynamic Monitoring, providing continuous and noninvasive hemodynamic insights to reduce the risk of severe complications for patients with low blood pressure.
  • In September 2019, Baxter International Inc. entered into a definitive agreement to acquire Cheetah Medical, a leading provider of non-invasive hemodynamic monitoring technologies.

For more insights into Hemodynamic Monitoring Systems Market, get the snapshot of the key highlights entailed in the Hemodynamic Monitoring Systems Report

View Report: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market

Hemodynamic Monitoring Systems Overview

In medical contexts, the term “hemodynamics” often refers to basic measures of cardiovascular function, such as arterial pressure or cardiac output. It is the physical study of flowing blood and of all the solid structures (such as arteries) through which it flows. The circulatory system is controlled by homeostatic mechanisms of autoregulation, just as hydraulic circuits are controlled by control systems. The hemodynamic response continuously monitors and adjusts to conditions in the body and its environment. Blood flow ensures the transportation of nutrients, hormones, metabolic waste products, oxygen, and carbon dioxide throughout the body to maintain cell-level metabolism, the regulation of the pH, osmotic pressure and temperature of the whole body, and the protection from microbial and mechanical harm. Hemodynamics explains the physical laws that govern the flow of blood in the blood vessels.

Hemodynamic monitoring systems are measurement tools and their effects on outcomes are only as good as the protocols they are used to drive. Hemodynamic monitoring in the critical care setting and in the perioperative period has been studied for decades and has generated a still increasing number of publications. 

Interested in knowing how the Hemodynamic Monitoring Systems will be growing by 2026? Click to get a snapshot of  Hemodynamic Monitoring Systems Analysis

View Report: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market

Geography Wise- Hemodynamic Monitoring Systems Market Analysis

The Hemodynamic Monitoring Systems market is analyzed geographically for North America, Europe, Asia-Pacific, and the Rest of the World. Among all the regions, North America is expected to account for the largest share in the global Hemodynamic Monitoring Systems market. Factors such as the rising prevalence of cardiovascular diseases and diabetes, technological advancement in product development, increasing geriatric population, rising government initiatives, and increased product launches are expected to aid in the growth of the North America Hemodynamic Monitoring Systems Market. Furthermore, high disposable income, sophisticated healthcare infrastructure, and increased awareness regarding disease progression and new treatments are also expected to aid in the Hemodynamic Monitoring Systems market growth in this region.

Segmentation

By Product 

  • Systems
  • Disposables

By Type 

  • Invasive Hemodynamic Monitoring
  • Minimally Invasive Hemodynamic Monitoring
  • Non-Invasive Hemodynamic Monitoring

By End-User 

  • Hospitals
  • Ambulatory Care Centers
  • Others

By Geography 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Get a sneak peek at the Hemodynamic Monitoring Systems Market market dynamics @ Hemodynamic Monitoring Systems Market Drivers Analysis

Hemodynamic Monitoring Systems Market Segment Analysis

In the Type segment of the Hemodynamic Monitoring Systems market, the Non-Invasive Hemodynamic Monitoring Systems are estimated to hold a significant share in the Hemodynamic Monitoring Systems market during the forecast period (2021-2026). These devices have fewer complications, are less expensive, and can be used in patients who need more in-depth monitoring of their hemodynamic status. Moreover, these devices can serve as a great alternative to invasive monitoring of blood pressure in patients who are out of the critical stage or undergoing elective procedures. Another added advantage associated with Non-Invasive Hemodynamic Monitoring Systems is that while intermittent blood pressure monitoring might be suitable in stable patients, use of the non-invasive continuous methods can be more appropriate in close monitoring of patients who are at risk of hemodynamic compromise or where the invasive methods would put patients at unnecessarily increased risk. Hence, their reliability has constantly increased with time and advancements in the newer generation of devices. Therefore, considering the advantages associated with Non-Invasive Hemodynamic Monitoring Systems, this category is expected to generate significant revenue share eventually contributing to the overall growth of the global Hemodynamic Monitoring Systems market in the forecast period.

View Report: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market

Hemodynamic Monitoring Systems Market Scope

Study Period: 2018-2026

Key Companies: Edwards Lifesciences Corporation, Getinge AB, Deltex Medical Limited, ICU Medical, Inc., CNSystems Medizintechnik GmbH, Caretaker, LLC, Osypka Medical GmbH, Baxter International Inc (Cheetah Medical, Inc.), Shenzhen Comen Medical Instruments Co., Ltd., General Meditech Inc., Drägerwerk AG & Co. KGaA, General Electric Company, Smiths Group, Transonic Systems Inc., EMTEL Śliwa sp. K, Koninklijke Philips N.V., NIMedical, Masimo (LiDCO Group Plc), Nihon Kohden Corporation, Hemo Sapiens Inc. and others.

Segmentation: By Product, By Type, By End-User, By geography

Geography Covered: North America, Europe, Asia- Pacific, Rest of the World (Middle East, Africa, and South America)

Know more about which MedTech player is set to emerge as the trendsetter @ Key Hemodynamic Monitoring Systems Companies

Table of Contents

  1. Hemodynamic Monitoring Systems Market Report Introduction
  2. Hemodynamic Monitoring Systems Market Executive Summary
  3. Regulatory and Patent Analysis
  4. Hemodynamic Monitoring Systems Market Key Factors Analysis
  5. Hemodynamic Monitoring Systems Market Porter’s Five Forces Analysis
  6. COVID-19 Impact Analysis on Hemodynamic Monitoring Systems Market
  7. Hemodynamic Monitoring Systems Market Layout
  8. Hemodynamic Monitoring Systems Market Global Company Share Analysis – Key 3-5 Companies
  9. Hemodynamic Monitoring Systems Market Company and Product Profiles
  10. KOL Views
  11. Project Approach
  12. About DelveInsight
  13. Disclaimer & Contact Us

Learn more about the Hemodynamic Monitoring Systems @ Hemodynamic Monitoring Systems Regulatory And Patent Analysis

Other Reports:

Related Blogs:

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/

Connect With Us at:

LinkedIn | Facebook | Twitter

Design a site like this with WordPress.com
Get started